Abstract: A method is provided for operating a gas concentration monitoring system as well as a gas-measuring device, a central unit, a gas concentration monitoring system as well as computer program product. The safety of persons or the safety of a situation is determined with respect to at least one hazardous gas. The concentration of the gas is provided to a memory and analysis device. A measured value rating number is determined for a preset period of use. A number of instances, of the measured concentration values exceeding of a preset gas concentration limit value is input. A safety code is determined from at least one of: the measured concentration values, the measured value rating numbers and from the a total number of instances in which a gas concentration limit value was exceeded.

Abstract: A system for stabilizing sensor readings. The system includes a processor; a memory communicatively coupled to the processor; a receiver to receive from a sensing device, a measurement and an environmental parameter. The system also includes a machine learning engine executed on the processor wherein the machine learning engine receives, as inputs: the environmental parameters; the measurement; and control parameters calculated based on control measurements made at time points before and after the measurement.

Abstract: The invention relates to a method for the quantification of the total gluten content of grains in food samples. Areas of application are primarily the food industry, service laboratories and government test laboratories or biotechnology. The invention aims to quickly and cost-effectively determine the total gluten content in foods with just one measurement. We include a method with which, based on the detection of prolamins and glutelins, all potentially coeliac-relevant gluten protein fractions in food samples are quantified as a total corresponding to their mass. The method is based on the joint use of specific prolamin and glutelin antibodies as a combined conjugate according to the invention for the detection of the total gluten content. In addition, the individual antibody conjugates are thinned so that the contribution of the individual antibodies to the total signal strength corresponds to the proportion of the gluten fraction that they each detect.

Abstract: Embodiments of a water detection apparatus are disclosed that can detect characteristics of food products. The apparatus may include a conveying mechanism configured to move a food product through an aperture in the apparatus, a transmitter coil configured to transmit a signal within the aperture, and a receiver coil configured to receive the signal altered by the food product, and a signal processing unit configured to determine an output value associated with the food product moving through the aperture. The output value can be based, at least in part, on the signal and the altered signal. The output value can corresponds to a characteristic of the food product.

Abstract: The invention relates to the fields of process engineering and agriculture and relates to a method for in-ovo fertilisation determination and gender determination on a closed egg. The aim of the invention is to specify a method for the in-ovo fertilisation determination and gender determination on a closed egg. This aim is achieved by a method in which a closed egg is positioned, candled and/or illuminated, next an image of the closed egg is recorded, then the captured data are evaluated and the position of the cardiovascular system located in the egg is calculated. A detection unit is adjusted via the calculated position of the cardiovascular system by means of a positioning unit and subsequently the blood is stimulated, then the blood-specific and blood-foreign absorption spectra are detected and selected, the fertilisation is ascertained and then the spectra containing blood-foreign information are compensated by a compensation method and the spectra are classified for sex determination.

Abstract: A particulate lanthanide-doped material comprising an inorganic host phosphor and a lanthanide ion dopant. With the lanthanide-doped material being in an oxidized state, photoluminescence is suppressed. Photoluminescence of the material can be activated by the presence of a reducing substance that reduces the lanthanide-doped material in a redox interaction. The lanthanide-doped material can be used for biodetection (e.g. detecting the presence of microorganisms in a sample). This could have numerous applications, such as detecting the presence of contaminating microorganisms in a sample (e.g. in a food or cosmetic product).

Abstract: The invention relates to a device and method for laboratory ice jam and ice dam radar measurement tests, the device includes a non-metal water tank, a truss spans the top of the non-metal water tank, the truss is connected with a radar plate parallel to a surface of water through a lifting mechanism, a measuring radar is provided on the radar plate, a permeable measuring barrel soaked in the water is provided below the radar plate, a barrel bottom of the permeable measuring barrel is a permeable plate capable of rising and falling, model ice blocks are provided in the permeable measuring barrel, and a handle capable of shaking the truss upwards, downwards, leftwards and rightwards is provided on the truss.

Abstract: A liquid monitoring system includes a remote measurement device located at a location of the fire hydrant that is in contact with water provided by a water main. The remote measurement device has sensors that measure characteristics of the water and/or acoustic vibrations in the water and a communication interface that transmits measured information to a communication network device that may be located elsewhere on the fire hydrant. The communication network device communicates with a communication network.

Abstract: A laboratory tracer experiment system based on karst conduit medium characteristic inversion, having: a assembly model system of the karst conduit medium; a test bed, configured to support the assembly model system of the karst conduit medium; a water supply system connected to the assembly model system of the karst conduit medium to supply water to the assembly model system of the karst conduit medium; a full-automatic control system for tracer adding connected to the assembly model system of the karst conduit medium to add a prepared tracer solution into the assembly model system of the karst conduit medium; a real-time wireless monitoring system of fluorescent tracer; and a central control system for controlling the full-automatic control system for tracer adding, the water supply system, the real-time wireless monitoring system of fluorescent tracer and the high-definition camera recording system to communicate with the central control system.

Abstract: A method and system to determine mass fraction of aromatic hydrocarbons, sulfur-multi-sulfur, sulfur-nitrogen, multi-sulfur-multi-nitrogen, and nitrogen containing aromatic compound classes present within a petroleum sample. The invention uses total sulfur determination, total nitrogen determination, and elemental formulas determination, with the latter determined through time-of-flight mass spectrometric analysis with atmospheric pressure photo ionization and Fourier-transform ion-cyclotron resonance mass spectrometric analysis with atmospheric pressure photo ionization.

Abstract: The application provides an improved gemstone testing apparatus for testing a gemstone specimen. The gemstone testing apparatus includes a handheld casing, a processor unit, a first gemstone test device, a second gemstone test device, and a display unit. The first gemstone test device includes a first test probe and a thermal conductivity test module. The second gemstone test device includes a second test probe and a light absorption module.

Abstract: In an aspect, disclosed herein are physiological devices and systems, and components thereof, used to evaluate cardiac parameters and arrhythmogenic mechanisms. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: In a method for sensing translocation of a molecule through a nanopore, a molecule in a first fluidic solution in a first fluidic reservoir that is in direct fluidic connection with the nanopore is directed to a nanopore inlet and translocated through the nanopore to a nanopore outlet and through a fluidic passage that is in direct fluidic connection with the nanopore outlet, to a second fluidic solution in a second fluidic reservoir disposed in direct fluidic connection with the fluidic passage. The fluidic passage has at least one fluidic section in which a length of the fluidic section is greater than a width of the fluidic section. Translocation of the molecule through the nanopore is sensed by measuring the electrical potential local to the fluidic passage during the translocation of the molecule.

Abstract: A first fluidic solution having a first ionic concentration is provided in a first fluidic reservoir in direct fluidic connection with a nanopore. A second fluidic solution, having a second ionic concentration, is provided in a second fluidic reservoir disposed in fluidic connection with the nanopore through a fluidic passage having at least one fluidic section in which the section length is greater than the section width. The electrical potential local to the fluidic passage is measured, and the resistance of both the fluidic passage the nanopore are determined based on the fluidic passage electrical potential. The fluidic passage resistance is compared with the nanopore resistance and at least one of the first and second ionic concentrations is adjusted based on the comparison. The measuring, determining, comparing, and adjusting steps are conducted until the fluidic passage resistance is between about 0.1 times and about 10 times the nanopore resistance.

Abstract: The present invention concerns a method for determining the impact of a production step or a purification step on the presence or nature of pro-inflammatory contaminating molecules in glucose polymers or the hydrolysates of same by using an in vitro test of inflammatory response using cell lines. It further concerns an optimised method of producing or purifying glucose polymers or the hydrolysates of same comprising an analysis of the pro-inflammatory contaminating molecules in glucose polymers or the hydrolysates of same and the selection of production or purification steps optimised with respect to the presence and nature of the pro-inflammatory contaminating molecules.

Abstract: The present invention discloses, in one embodiment, a method of using human induced pluripotent stem cells to generate three-dimensional human organ tissue for therapeutic drug toxicity and discovery. In one embodiment, a high throughput microtiter plate is loaded with both wild type and Rett disease 3D spheroids and exposed to a drug library, and activity is measured and analyzed for disease rescue to wild type cell behavior.

Abstract: Disclosed is an ex vivo model for subcutaneous injection and aims at providing an in vitro method including the steps of i) immersing a skin explant in a solidifiable liquid matrix such that the upper face of the epidermis is not covered, which matrix is itself contained in a cell culture insert, the bottom of which consists of a porous membrane, and (ii) solidifying this matrix so as to trap the immersed portion of this skin explant, wherein the upper face of the epidermis is not covered, and adhering this same matrix to the side walls and the porous membrane of the insert, wherein the skin explant includes a thickness of at least 5 mm of hypodermis.

Abstract: The present invention provides a method for predicting a therapeutic effect and/or monitoring recurrence in a cancer patient. Disclosed is a method for detecting a therapeutic effect of cancer treatment in a cancer patient, comprising: measuring nematode tactic behavior to each of pre-treatment urine and in-treatment or post-treatment urine from the cancer patient; and comparing a result of measuring the tactic behavior to the pre-treatment urine and a result of measuring the tactic behavior to the in-treatment or post-treatment urine, wherein when attraction is weakened or avoidance is strengthened after the treatment, it is determined that the therapeutic effect is detected.

Abstract: The present invention relates to a method for determining an analyte in a sample, comprising a) contacting said sample with at least a first and a second detector compound; b) determining the amount of complexes comprising at least one detector compound; and, c) determining said analyte in a sample based on the result of step b), wherein said first detector compound comprises a first binding moiety and a first label, and said second detector compound comprises a second binding moiety and a second label, and wherein the first label and the second label are non-identical.

Abstract: Disclosed herein is a protein-based, genetically-encoded bioluminescent sensor that can report changes in intracellular ATP in live cells. This sensor is built from the NanoLuc luciferase (Promega) and mScarlet red fluorescent protein (DOI: 10.1038/nmeth.4074) in a novel platform that provides a much more quantitative optical signal for measurements. Analytical Chemistry demonstrates its characterization and that it can be used to image ATP differences in live cells under the skin of mice. This new sensor can be very useful for research purposes in cancer biology to measure cell health and chemotherapeutic drug efficacy for example in animal models of tumors or in cell-based screening.

Abstract: The present application is directed to a composite material comprising a core that is responsive to a magnet or a magnetic field, surrounded by a polymer that has been chemically modified to spontaneously bind and assemble a dense corona of fluorescent quantum dots, which is then over-coated with another layer of modified polymer that can be bound by an antibody complex for targeting specific antigens. Methods of preparing and using this material for the detection and quantification of target antigens is also included in the application.

Abstract: Provided are methods and compositions for the production of novel antibodies that bind specifically to a target antigen. These methods and compositions are particularly useful for producing antibodies having the antigen binding specificity of a reference antibody but with improved properties (e.g., binding affinity, immunogenicity, and thermodynamic stability) relative to the reference antibody.

Abstract: The present disclosure provides, in one aspect, a target substance detection method in which a trapping substance that indirectly binds to both an immobilization side (support side) and a detection side (reporter side), which is a method for detecting a target substance in a sample. The method includes a reaction step of reacting the sample, a support including a first binding portion, a reporter substance including a second binding portion, a first trapping substance that includes a first binding partner portion capable of binding to the first binding portion and that can bind to the target substance, and a second trapping substance that includes a second binding partner portion capable of binding to the second binding portion and that can bind to the target substance; and a detection step of detecting a signal from the reporter substance.

Abstract: Disclosed herein systems, apparatuses and methods for the collection and testing of biological samples, and more specifically to rapid and simple methods for diagnosis of various diseases, conditions, or symptoms via the testing of collected biological samples on paper devices.

Abstract: A method for processing an analyte includes: adding a plurality of amphiphilic nanoparticles to a solvent to form a mixture having a plurality of enantioselective nanoparticle ensembles; adding an analyte to the mixture; obtaining a test circular dichroism spectrum of the mixture with the analyte; and determining an enantiomeric property of the analyte based on a comparison of a baseline circular dichroism spectrum of the analyte mixture to the test circular dichroism spectrum.

Abstract: The bio sensor platform is a rapid point-of-care (POC) device wherein detection of a target analyte from a liquid or solid substrate is performed in a single step using a fully integrated disposable test system that includes a test strip immunoassay. In operation, a user initiates the test by rupturing the bottom of a liquid-filled analyte capsule seated in a capsule sleeve. A small volume of liquid flows by capillary action from the capsule sleeve and through a restrictor port to a test strip chamber where contact with the absorptive sample pad of the test strip (among other things) moves liquid by capillary action upwardly through the test strip. The detection of the target analyte is resolved by the test strip reagents and the test results are obtained at a test result window where a portion of the test strip is exposed to the user.

Abstract: Provided are methods of reducing and/or preventing interference by a drug comprising (i) an antibody Fc region and (ii) a moiety that binds to human CD47 in serological assays.

Abstract: Silica nanoparticles for biomarker diagnosis and a method of manufacturing the same, and more particularly silica nanoparticles for biomarker diagnosis capable of measuring glycated proteins such as glycated hemoglobin, glycated albumin, etc. used as diabetes diagnosis markers, and a method of manufacturing the same are proposed. The silica nanoparticles for biomarker diagnosis, containing a reactive polymer and a nonreactive polymer immobilized on the surface and a dye immobilized inside, immobilize the dye therein through covalent bonding, whereby the dye is not affected by external environmental factors such as heat, pH, etc., and stability is enhanced even upon long-term storage.

Abstract: An embodiment of this invention A NiO chip is provided. The NiO chip includes a substrate, a nickel oxide thin film on the substrate, and a bioprobe layer on the nickel oxide thin film. The nickel oxide thin film has a light transmittance of more than 60% and a nanostructure. The bioprobe layer includes a plurality of bioprobes modified by Histidine (His) or a His-tagged protein.

Abstract: A diagnostically useful carrier includes a means for specifically capturing an antibody to a polypeptide from the group including squid MLC1 or squid MLC2 or a variant thereof in a sample from a subject. A method includes the step detecting in a sample from a subject the presence or absence of an antibody to squid MLC1 or squid MLC2. The polypeptide or the carrier or a polypeptide binding specifically to an IgE antibody from the sample of a patient to squid MLC1 or squid MLC2 are useful for the manufacture of a diagnostic kit, preferably for the diagnosis of allergy.

Abstract: The present invention provides a diagnostic method which may be used to determine the likelihood that a subject with Irritable Bowel Syndrome (IBS) will respond to treatment with an IBS intervention diet or faecal microbiota transplant (FMT). In particular, the method may be used to predict, or determine the likelihood of, a positive response of the subject with IBS to treatment with an IBS intervention diet or FMT, especially to determine the likelihood that the dietary intervention or FMT may have a positive (i.e. beneficial) effect on the subject's GI tract, specifically the GI tract microbiota, or other symptoms or complications of IBS (e.g. reducing severity thereof). The method of the present invention is based on analysing the abundance of certain bacteria in GI tract samples, e.g. by nucleic acid analysis.

Abstract: Provided herein is a method for multiplexed detection of a plurality of targets, including targets associated with a measles (M) virus and a rubella (R) virus, including a M vaccine, a R vaccine, or a MR vaccine. A plurality of capture agents specific to a measles target and a rubella target are provided on a substrate, wherein the capture agents specifically bind to the measles target and the rubella target. Contacting the plurality of capture agents with a sample forms a capture agent-target complex which can be detected by a corresponding spatial pattern of capture agent-target complex.

Abstract: The present invention provides methods of detecting infection using biomarkers. The methods disclosed herein include measuring the expression level of one or more polypeptide determinants in which the alteration of the expression level indicates infection of the patient. The methods provided herein are for distinguishing between bacterial infection, mixed infection, and/or viral infection. The methods disclosed herein may also further comprise measuring one or more non-polypeptide determinants. The present disclosure also provides methods for selection of a treatment regimen for the subject based on whether the subject is identified as having a bacterial or mixed infection, or a viral infection.

Abstract: A method of preparing an antibody therapeutic is provided comprising: (a) providing a dissociated cell sample from at least one solid tumor sample obtained from a patient; (b) loading the dissociated cell sample into a microfluidic device having a flow region and at least one isolation region fluidically connected to the flow region; (c) moving at least one B cell from the dissociated cell sample into at least one isolation region in the microfluidic device, thereby obtaining at least one isolated B cell; and (d) using the microfluidic device to identify at least one B cell that produces antibodies capable of binding to cancer cells. The cancer cells can be the patient's own cancer cells. Also provided are methods of treating patients, methods of labeling or detecting cancer, engineered T or NK cells comprising antibodies or fragments thereof, and engineered antibody constructs.

Abstract: Disclosed herein are ATP biosensor fusion proteins and their use for assaying ATP levels in cells.

Abstract: The present invention provides reagents and methods for breast cancer detection.

Abstract: The present invention provides compositions including reagents for detecting human autoantibodies against at least two proteins selected from the group consisting of ANGTPL4, DKK1, EPHA2, LAMC2, SPON2, SSR2, GAL1, GFRA1, LRRC15, CD147, CD320, CDH3, LRP10, SPINT2, SUSD2, and CST2, and their use in detecting breast cancer or disease recurrence.

Abstract: Described herein are non-invasive or minimally invasive methods and compositions for collecting and assessing samples for detection of gastrointestinal (GI) tract cancers and pancreatic cancers. Samples comprising gastrointestinal lavage fluid (GLF) are obtained from subjects and screened against a glycan microarray to reveal disease-specific glycan-binding patterns by immunoglobulins contained in the GLF, especially immunoglobulin A (IgA). The disease-specific glycan-binding patterns include a disease-specific glycan or subset of glycans from the microarray that are bound by the immunoglobulins in GLF at highest intensities or at lowest intensities, as well as one or more glycan motifs found within this disease-specific subset of glycans.

Abstract: The present invention provides a method of detecting MAGEA4 in a sample. The method may comprise adding an anti-MAGEA4 antibody to the sample at a concentration in the range of from 2-20 ?g/ml, incubating the antibody and the sample and detecting antibody that is bound to the sample. The methods of the invention can be used to diagnose whether a subject has cancer and whether the subject is eligible for treatment with a MAGEA4 targeted cancer therapy.

Abstract: Methods for selecting patients responsive to immune checkpoint inhibitors are herein disclosed. Methods of treating cancer patients with an immune checkpoint inhibitor are also provided.

Abstract: Described are methods for providing personalized medicine for the treatment of B cell malignancies including lymphoma. The methods make use of Chimeric Antigen Receptor (CAR) technology.

Abstract: The invention, in part, includes methods of single molecule protein sequencing that include using weak binding spectra in the amino acid identification.

Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Accordingly, these compounds can be used as modulators of TNF. A new assay for identifying compounds with this mechanism of action is also disclosed.

Abstract: Compositions and methods are provided for the identification of peptide sequences that are ligands for a T cell receptor (TCR) of interest, in a given MHC context.

Abstract: Compositions and methods are provided for the identification of peptide sequences that are ligands for a T cell receptor (TCR) of interest, in a given MHC context.

Abstract: The invention is in the field of in vitro diagnostics and relates to a method for quantitatively determining therapeutic TNF-alpha inhibitors.

Abstract: Biomarkers useful for diagnosing and assessing inflammatory disease are provided, along with kits for measuring their expression. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. The biomarkers include at least two biomarkers selected from the DAIMRK group and the score is a disease activity index (DAI).

Abstract: The disclosure provides compositions and methods for the detection of renal disease and periodontal disease in mammals.

Abstract: The present invention provides a method for the early diagnosis, prognosis and differentiation of ischemic cardiac events in myocardial ischemia by a Nourin gene-based RNA molecular network of biomarkers to: (a) diagnose unstable angina and AMI (STEMI and NSTEMI) patients, and differentiate between unstable angina and AMI; (b) diagnose ACS patients and differentiate them from symptomatic non-cardiac patients and healthy subjects; (c) diagnose angina in suspected patients with history of chest pain and differentiate angina patients from symptomatic non-angina and healthy subjects; and (d) diagnose “new-onset” heart failure and provide a prognostic value and risk prediction of progression and deterioration, as well as monitoring patients' response to treatments. Downregulation of Nourin-related lncR-CTB9H12.

Abstract: The invention relates to biomarkers for typing or classifying allograft recipients as belonging to a transplant rejection group associated with antibody-mediated rejection (ABMR). The invention also provides for the treatment of typed allograft recipients suffering from antibody-mediated rejection by administration of an appropriate therapeutic agent.